Potential Cost of Multi-Cancer Detection Tests to Medicare
Scherer, L. D.; Matlock, D. D.; Cronin, J.; Gritz, M.
Show abstract
Multi-Cancer Detection (MCD) tests can detect more than 50 different types of cancer using a blood test. Recently passed law in the U.S. guarantees that Medicare will pay for these tests when they are FDA approved and show evidence for clinical benefit. This manuscript provides estimates of the cost of MCD tests to Medicare under different assumptions of cost per test, eligibility, and screening uptake in the eligible population. This manuscript additionally estimates the cost of follow-up testing resulting from false positive results, which are considered avoidable costs caused by the screening test.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Pricing Treatments Cost-Effectively When They Have Multiple Indications: Not Just a Simple Threshold Analysis 90%
- Forecasting local surges in COVID-19 hospitalizations through adaptive decision tree classifiers 90%
- A novel decision modeling framework for health policy analyses when outcomes are influenced by social and disease processes 88%
Similar papers in this journal
- AI-Driven Early Detection of Severe Influenza in Jiangsu, China: A Deep Learning Model Validated Through The Design of Multi-Center Clinical Trials and Prospective Real-World Deployment 88%
- Projecting the impact of SARS-CoV-2 variants on the COVID-19 epidemic and social restoration in the United States: a mathematical modelling study 88%
- Budget Impact Analysis Of The Introduction Of Ranibizumabs Biosimilar To The Jordanian Joint Procurement System. 88%
Similar papers in this journal
- Clinical Benefits and Budget Impact of Lenzilumab plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with COVID-19 in the United States from the Hospital Perspective 89%
- Comparison of healthcare resource use and cost between influenza and COVID-19 vaccine coadministration and influenza vaccination only 88%
- Reflex single-gene non-invasive prenatal testing significantly increases the cost-effectiveness of carrier screening 88%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.